MapLight Therapeutics entered into a Securities Purchase Agreement for a $150 million private placement, selling 9,197,887 shares of common stock and pre-funded warrants to purchase 3,983,168 additional shares at a price of $11.38 per share. The company also reported Q2 2026 financial results, including a net loss of $60.2 million and R&D expenses of $53.4 million, while holding $351.3 million in cash as of June 30, 2026. Clinically, the company announced positive Phase 2 ZEPHYR trial results for its schizophrenia candidate ML-007C-MA, which met its primary endpoint and supports advancement into a registrational Phase 3 ZEPHYR-2 trial. MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders.

MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA for schizophrenia. The 210/3 mg BID dose met the primary endpoint, demonstrating a statistically significant reduction in PANSS total score compared to placebo (effect size 0.37, p=0.015) at Week 5. The trial also showed significant improvement in a prespecified secondary cognitive performance endpoint (effect size 0.51, p=0.041). The drug was generally well tolerated with no serious or drug-related severe adverse events and a 19.9% all-cause discontinuation rate across active arms. The company plans to engage the FDA for an End-of-Phase 2 meeting to discuss a confirmatory Phase 3 trial to support an initial NDA submission. MapLight Therapeutics is a biopharmaceutical company developing treatments for central nervous system disorders.

MapLight Therapeutics, Inc. announced the topline results from the IRIS (ML-004-002) Phase 2 study of ML-004 in autism spectrum disorder. The company will hold a conference call on June 22, 2026, to discuss these trial results. MapLight Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for neurological and neurodevelopmental disorders.

MapLight Therapeutics, Inc. announced the immediate separation of CFO Vishwas Setia on June 18, 2026, following a human resources violation. The company's board of directors appointed Jonathan Gillis, the current Chief Administrative and Accounting Officer, to serve as interim CFO and interim principal financial officer, effective immediately. MapLight Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.